Photocure Crescita futura

Future criteri di controllo 4/6

Photocure prevede che gli utili e i ricavi cresceranno rispettivamente di 94.9% e 13% all'anno. Si prevede che l'EPS crescerà di 94.8% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 16.2% in 3 anni.

Informazioni chiave

94.9%

Tasso di crescita degli utili

94.8%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	15.9%
Tasso di crescita dei ricavi	13.0%
Rendimento futuro del capitale proprio	16.2%
Copertura analitica	Low
Ultimo aggiornamento	22 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Analyst Estimates: Here's What Brokers Think Of Photocure ASA (OB:PHO) After Its Second-Quarter Report

Aug 14

We Think Photocure (OB:PHO) Can Stay On Top Of Its Debt

Aug 12

Do Institutions Own Photocure ASA (OB:PHO) Shares?

Feb 11

Photocure ASA's (OB:PHO) Stock Is Going Strong: Have Financials A Role To Play?

Jan 21

The Photocure (OB:PHO) Share Price Is Up 286% And Shareholders Are Boasting About It

Dec 31

We're Not So Sure You Should Rely on Photocure's (OB:PHO) Statutory Earnings

Dec 09

Previsioni di crescita degli utili e dei ricavi

OB:PHO - Stime future degli analisti e dati finanziari passati (NOK Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	644	72	64	122	2
12/31/2025	545	15	6	37	2
12/31/2024	502	7	38	65	2
9/30/2024	526	14	71	81	N/A
6/30/2024	514	13	41	56	N/A
3/31/2024	512	5	49	63	N/A
12/31/2023	501	1	36	48	N/A
9/30/2023	462	-34	18	29	N/A
6/30/2023	462	-39	36	42	N/A
3/31/2023	418	-62	6	11	N/A
12/31/2022	393	-72	-6	-2	N/A
9/30/2022	383	-79	2	4	N/A
6/30/2022	364	-76	-16	-12	N/A
3/31/2022	354	-68	1	4	N/A
12/31/2021	361	-31	20	24	N/A
9/30/2021	364	7	191	29	N/A
6/30/2021	326	9	12	13	N/A
3/31/2021	290	10	9	11	N/A
12/31/2020	256	-22	14	16	N/A
9/30/2020	274	10	-134	35	N/A
6/30/2020	285	15	53	55	N/A
3/31/2020	284	19	37	39	N/A
12/31/2019	282	32	20	21	N/A
9/30/2019	216	-23	0	1	N/A
6/30/2019	199	-27	-15	-14	N/A
3/31/2019	192	-39	-23	-21	N/A
12/31/2018	182	-37	-26	-24	N/A
9/30/2018	171	-38	-31	-28	N/A
6/30/2018	162	-43	N/A	-26	N/A
3/31/2018	156	-31	N/A	-31	N/A
12/31/2017	151	-35	N/A	-24	N/A
9/30/2017	150	-4	N/A	19	N/A
6/30/2017	149	6	N/A	14	N/A
3/31/2017	145	29	N/A	18	N/A
12/31/2016	144	35	N/A	19	N/A
9/30/2016	140	8	N/A	-33	N/A
6/30/2016	141	3	N/A	-29	N/A
3/31/2016	140	-26	N/A	-18	N/A
12/31/2015	135	-36	N/A	-21	N/A
9/30/2015	126	-58	N/A	-22	N/A
6/30/2015	147	-29	N/A	8	N/A
3/31/2015	138	-23	N/A	1	N/A
12/31/2014	129	-25	N/A	-6	N/A
9/30/2014	129	-2	N/A	-21	N/A
6/30/2014	92	-39	N/A	-64	N/A
3/31/2014	89	-50	N/A	-92	N/A
12/31/2013	84	-59	N/A	-100	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di PHO ( 94.9% all'anno) è superiore al tasso di risparmio ( 2.4% ).

Guadagni vs Mercato: Si prevede che gli utili di PHO ( 94.9% all'anno) cresceranno più rapidamente del mercato Norwegian ( 9.5% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di PHO cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di PHO ( 13% all'anno) crescerà più rapidamente del mercato Norwegian ( 2.3% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di PHO ( 13% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di PHO sarà basso tra 3 anni ( 16.2 %).

Photocure Crescita futura

Future criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus EPS estimates fall by 18%

Consensus EPS estimates have been upgraded.

Consensus EPS estimates fall by 17%

Consensus EPS estimates increase from loss to kr0.019 profit

Photocure ASA Reiterates Financial Guidance for the Year 2024

Consensus EPS estimates fall from profit to kr0.58 loss

Recent updates

Consensus EPS estimates fall by 18%

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates have been upgraded.

Consensus EPS estimates fall by 17%

We Think Photocure's (OB:PHO) Robust Earnings Are Conservative

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates increase from loss to kr0.019 profit

Photocure ASA's (OB:PHO) P/S Still Appears To Be Reasonable

Photocure ASA Announces Board Appointments

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Photocure ASA Reiterates Financial Guidance for the Year 2024

Consensus EPS estimates fall from profit to kr0.58 loss

Photocure ASA Announces Pivotal Trial Results and New Real-World Evidence

Photocure ASA Announces the Publication of the Study Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Consensus EPS estimates increase by 50%, revenue downgraded

Price target decreased by 7.0% to kr86.00

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Forecast breakeven date pushed back to 2025

Photocure ASA to Report Q4, 2023 Results on Feb 21, 2024

Photocure ASA's (OB:PHO) 26% Jump Shows Its Popularity With Investors

Photocure ASA Partner Asieris Announces New Drug Application Acceptance for Regulatory Review of Hexvix in China

Third quarter 2023 earnings released: kr0.18 loss per share (vs kr0.37 loss in 3Q 2022)

Photocure ASA Announces Change of Board Composition

Director recently bought kr6.5m worth of stock

Potential Upside For Photocure ASA (OB:PHO) Not Without Risk

Price target decreased by 10.0% to kr90.00

Photocure Partner Asieris Confirms Hexvix Phase III Clinical Trial in China Meets Endpoint

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Photocure Partner Asieris Announces Completion of Enrollment for Hexvix Phase III Clinical Trial in China

Insufficient new directors

Consensus estimates of losses per share improve by 15%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Time To Worry? Analysts Just Downgraded Their Photocure ASA (OB:PHO) Outlook

Price target decreased by 7.7% to kr120

Forecast breakeven date pushed back to 2024

Full year 2022 earnings released: kr2.66 loss per share (vs kr1.15 loss in FY 2021)

Photocure Asa Announces Clinical Data Presented At ASCO GU Demonstrates Reduced Risk of Recurrence in Non-Muscle Invasive Bladder Cancer with the Use of BLC

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure ASA to Report First Half, 2023 Results on Aug 09, 2023

Photocure ASA Announces New Evidence Presented At the 22nd Annual Society of Urologic Oncology Meeting Demonstrating That Blue Light Cystoscopy

Price target decreased to kr125

Third quarter 2022 earnings released: kr0.37 loss per share (vs kr0.27 loss in 3Q 2021)

Photocure Asa Announces Data Presented At the International Bladder Cancer Network (Ibcn) Meeting Demonstrate A Reduction in the Risk of Recurrence with the Use of Blc

PPhotocure ASA Announces the Commercial Availability of Karl Storz's New Blue Light System in the U.S

Photocure ASA Publishes First Results from Laser III Clinical Study in Medical Journal, European Urology

Photocure ASA Announces Continue E Supporting the Global Launch Activities of the New and Improved Blue Light Cystoscopy

Photocure ASA Appoints Anders Neijber as Chief Medical Officer, Global Medical Affairs and Clinical Development

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to kr135

Photocure Asa Provides Update on Anticipated Commercial Availability of Karl Storz's New Blue Light System in the United States

Photocure ASA Presents Positive Data from the Danish National Patient Registry at the 2022 NordUrologisk Forening (NUF) Congongress in Helsinki

Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on April 28, 2022.

President & CEO exercised options to buy kr10m worth of stock.

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Photocure Announces Endotherapeutics Group as New Commercial Partner for Hexvix in Australia & New Zealand

Photocure ASA Announces the Publication of Pre-Clinical Study Results Supporting the Anti-tumor Effect of Hexaminolevulinate with Blue Light in Bladder Cancer model

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Photocure ASA Receives FDA Approval for Use in NMIBC in the U.S

Consensus EPS estimates fall to -kr0.53

Third quarter 2021 earnings released: kr0.27 loss per share (vs kr0.23 loss in 3Q 2020)

Insider exercised options to buy kr2.8m worth of stock.

Consensus EPS estimates fall to -kr0.53

Analyst Estimates: Here's What Brokers Think Of Photocure ASA (OB:PHO) After Its Second-Quarter Report

We Think Photocure (OB:PHO) Can Stay On Top Of Its Debt

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.37 loss in 2Q 2020)

Photocure ASA Announces the Publication of a Study in the Journal Urologic Oncology

Asieris Announces First Patient Administration in Europe within the Phase III Clinical Trial for APL-1702 (Cevira)